^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Chk1 inhibitor

    Related drugs:
    Apply
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448)
    Phase 1/2
    Esperas Pharma Inc.
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/16/2016
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor (NCT05275426)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    03/02/2022
    Primary completion :
    03/02/2025
    Completion :
    03/02/2025
    WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4
    |
    EWSR1-WT1 fusion
    |
    gemcitabine • ESP-01
    Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02808650)
    Phase 1
    Children's Oncology Group
    Completed
    Last update posted :
    12/20/2023
    Initiation :
    02/27/2017
    Primary completion :
    12/31/2019
    Completion :
    03/31/2021
    AFP
    |
    TP53 mutation • TP53 deletion • TP53 expression
    |
    prexasertib (ACR-368)
    LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer (ExIST) (NCT04032080)
    Phase 2
    Baylor Research Institute
    Completed
    Last update posted :
    09/11/2023
    Initiation :
    09/05/2019
    Primary completion :
    06/01/2022
    Completion :
    11/26/2022
    ER
    |
    ER negative
    |
    prexasertib (ACR-368) • samotolisib (LY3023414)
    A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects (NCT02797977)
    Phase 1/2
    Sierra Oncology LLC - a GSK company
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    07/01/2016
    Primary completion :
    04/08/2020
    Completion :
    04/08/2020
    TP53 • BRCA1 • BRCA2 • MSI • RB1 • CCNE1 • BRCA
    |
    MSI-H/dMMR • BRCA wild-type
    |
    cisplatin • gemcitabine • SRA737
    A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer (NCT02797964)
    Phase 1/2
    Sierra Oncology LLC - a GSK company
    Completed
    Last update posted :
    06/16/2023
    Initiation :
    07/01/2016
    Primary completion :
    10/28/2019
    Completion :
    10/28/2019
    TP53 • BRCA1 • BRCA2 • MSI • CCNE1 • RAD50
    |
    MSI-H/dMMR
    |
    SRA737
    A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/21/2022
    Initiation :
    10/12/2016
    Primary completion :
    09/30/2020
    Completion :
    07/01/2021
    BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation
    |
    prexasertib (ACR-368)
    A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (NCT03414047)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/19/2022
    Initiation :
    04/10/2018
    Primary completion :
    06/03/2019
    Completion :
    10/03/2020
    BRCA1 • BRCA2 • BRCA
    |
    prexasertib (ACR-368)
    Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors (NCT03057145)
    Phase 1
    Geoffrey Shapiro, MD, PhD
    Completed
    Last update posted :
    09/02/2021
    Initiation :
    03/10/2017
    Primary completion :
    02/25/2020
    Completion :
    06/09/2021
    BRCA1 • BRCA2 • RAD51 • H2AX
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • prexasertib (ACR-368)
    A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (NCT03495323)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    04/15/2021
    Initiation :
    05/16/2018
    Primary completion :
    02/01/2021
    Completion :
    02/01/2021
    PD-L1 • H2AX
    |
    PD-L1 expression
    |
    prexasertib (ACR-368) • lodapolimab (LY3300054)
    A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (NCT02124148)
    Phase 1b
    Eli Lilly and Company
    Completed
    Last update posted :
    04/01/2020
    Initiation :
    06/18/2014
    Primary completion :
    02/13/2020
    Completion :
    02/13/2020
    HER-2 • KRAS • ER • PIK3CA • PGR
    |
    HER-2 overexpression • PIK3CA mutation • KRAS wild-type • RAS wild-type • ER negative • PGR negative
    |
    Erbitux (cetuximab) • cisplatin • 5-fluorouracil • pemetrexed • prexasertib (ACR-368) • leucovorin calcium • samotolisib (LY3023414)
    A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma (NCT01564251)
    Phase 1
    Genentech, Inc.
    Completed
    Last update posted :
    02/25/2020
    Initiation :
    03/23/2012
    Primary completion :
    01/11/2018
    Completion :
    01/11/2018
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    gemcitabine • RG7741
    A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    12/14/2018
    Initiation :
    08/10/2016
    Primary completion :
    05/15/2017
    Completion :
    05/15/2017
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation
    |
    prexasertib (ACR-368) • ralimetinib (LY 2228820)
    Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (NCT01870596)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/01/2016
    Initiation :
    05/01/2013
    Primary completion :
    12/01/2014
    Completion :
    12/01/2014
    CYP1A2
    |
    cytarabine • MK-8776